GLSI Stock Summary and Trading Ideas (Greenwich Lifesciences | NASDAQ:GLSI)

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Greenwich Lifesciences trades on the NASDAQ stock market under the symbol GLSI.

As of August 28, 2026, GLSI stock price declined to $15.67 with 367,389 million shares trading.

GLSI has a beta of 2.82, meaning it tends to be more sensitive to market movements. GLSI has a correlation of 0.14 to the broad based SPY ETF.

GLSI has a market cap of $209.48 million. This is considered a Small Cap stock.

In the last 3 years, GLSI traded as high as $34.10 and as low as $7.58.

The top ETF exchange traded funds that GLSI belongs to (by Net Assets): IWM, VTI, IWO, VXF, VFMO.

GLSI has outperformed the market in the last year with a return of +34.3%, while the SPY ETF gained +20.1%. However, in the most recent history, GLSI shares have underperformed the stock market with its stock returning -46.4% in the last 3 month period and -4.3% for the last 2 week period, while SPY has returned +2.8% and -1.1%, respectively.

GLSI support price is $17.70 and resistance is $19.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLSI shares will trade within this expected range on the day.